In this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.

We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!

In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice?

Hunault, et al. NEJM. 2025.

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326

In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice!

Join the Common Sense Oncology movement here! https://commonsenseoncology.org/

In this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!

Inspired by this recent paper:

https://www.nature.com/articles/s41408-025-01222-y

In this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AML? Tune in to find out!

In this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910.

Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe!

Finally, for all of the Oncology Pharmacists in the audience, don't forget to fill out the HOPA Practice Outcomes and Professional Benchmarking Committee Survey!

AQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion.

Note: L'aquila is Italian for eagle!

In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!

Some selected abstracts: